Pfizer said it plans to start 15 new studies in obesity next year, many of them in Phase 3, as it seeks to replace about

Link Cell Therapies launched Monday with a $60 million Series A round to fund the creation of the next wave of CAR-T therapies. The startup

Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide,

Hey, it’s Shelby. I’m back from maternity leave, during which I surprised myself by embracing health tech more than ever before. I’m admittedly a technology

Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.